Devyser Diagnostics

Devyser Diagnostics OCF Margin

The Operating Cash Flow Margin of Devyser Diagnostics (DVYSR.ST) as of Oct 19, 2026 is 3.27 %. In the previous year, Operating Cash Flow Margin was -21.58 % — a change of -115.17% (higher).

OCF Margin

3.27 %

YoY

-115.17%

Last updated:

Operating Cash Flow Margin of Devyser Diagnostics is 2025 3.27 % . Operating Cash Flow Margin of Devyser Diagnostics was 2024 -21.58 % . It decreases by -115.17% higher compared to the previous year.

The Devyser Diagnostics OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
12.50 SEK
Jan 1, 2019
22.75 SEK
Jan 1, 2020
0.95 SEK
Jan 1, 2021
-17.63 SEK
Jan 1, 2022
-31.99 SEK
Jan 1, 2023
-41.17 SEK
Jan 1, 2024
-21.58 SEK
Jan 1, 2025
3.27 SEK
The Devyser Diagnostics OCF Margin history
YEAROCF MarginYoY
3.27 %-115.17%
-21.58 %-47.59%
-41.17 %+28.70%
-31.99 %+81.43%
-17.63 %-1,947.19%
0.95 %-95.80%
22.75 %+81.98%
12.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Devyser Diagnostics Stock analysis

What does Devyser Diagnostics do? Devyser Diagnostics AB is a biotechnology company based in Hagersten, Sweden, operating within the healthcare sector. The company focuses on the development, manufacturing, and sale of genetic testing kits for routine diagnostics. It went public via an IPO on December 10, 2021, and currently employs 96 full-time staff. Devyser Diagnostics' products are utilized for complex DNA testing in areas such as hereditary diseases, oncology, and post-transplantation monitoring, aiding in the diagnosis of genetic conditions and guiding targeted cancer treatments. The company has developed and launched nearly 30 products for routine diagnostic use, including the Devyser Thrombophilia assay and Devyser Resolution XY, which analyzes chromosomes X and Y. These products are distributed directly to end customers or through hired distributors, with sales extending to over 45 countries. The company's website is www.devyser.com, and it is listed on the Stockholm Stock Exchange under the ticker DVYSR.ST. Devyser Diagnostics AB operates with a clear focus on providing diagnostic solutions that support medical professionals in identifying and managing genetic-related health issues through advanced testing technologies. Devyser Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Devyser Diagnostics stock

Operating Cash Flow Margin of Devyser Diagnostics is 3.27 % in 2025.

Operating Cash Flow Margin of Devyser Diagnostics changed from -21.58 % to 3.27 %, representing a -115.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Devyser Diagnostics since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Devyser Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Devyser Diagnostics

All Key Metrics — Devyser Diagnostics